December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

152.82 +6.41 (+4.38%)
Streaming Delayed Price Updated: 9:47 AM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
22 23 Next >
News headline image
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst ↗
Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth. 
Via Benzinga
News headline image
These S&P500 stocks are moving in today's pre-market session ↗
Curious about the S&P500 stocks that are showing activity before the opening bell on Friday? 
Via Chartmill
News headline image
Assessing Insulet: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 17.2% year on year to $597.5 million. Guidance for next... 
Via StockStory
News headline image
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year
From Insulet Corporation
Via Business Wire
News headline image
Earnings Scheduled For February 20, 2025 ↗
 
Via Benzinga
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:PODD. ↗
Based on Fundamental Analysis it can be said that NASDAQ:PODD is a growth stock which is not overvalued. 
Via Chartmill
News headline image
Insulet Earnings: What To Look For From PODD
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close. Here’s what to expect. 
Via StockStory
News headline image
$1000 Invested In Insulet 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Why NASDAQ:PODD Is a Standout High-Growth Stock in a Consolidation Phase. ↗
Based on a technical and fundamental analysis of NASDAQ:PODD we ask: Why INSULET CORP (NASDAQ:PODD) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
NASDAQ:PODD—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗
Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
News headline image
Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
From Insulet Corporation
Via Business Wire
News headline image
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Looking Into Insulet's Recent Short Interest ↗
 
Via Benzinga
News headline image
Stryker Had A Good Year Last Year; Here's How It's Looking For 2025 ↗
Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74. 
Via Investor's Business Daily
News headline image
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Insulet Corporation
Via Business Wire
News headline image
Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices ↗
Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
News headline image
Exploring the Growth Potential of NASDAQ:PODD as It Nears a Breakout. ↗
Why INSULET CORP (NASDAQ:PODD) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Decoding 11 Analyst Evaluations For Insulet ↗
 
Via Benzinga
News headline image
Novocure Stock Earns 96 RS Rating ↗
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73. 
Via Investor's Business Daily
News headline image
Peering Into Insulet's Recent Short Interest ↗
 
Via Benzinga
News headline image
Inari Medical Stock Gets RS Rating Upgrade ↗
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72. 
Via Investor's Business Daily
News headline image
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
From Insulet Corporation
Via Business Wire
News headline image
NASDAQ:PODD qualifies as a high growth stock and is consolidating. ↗
INSULET CORP (NASDAQ:PODD)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
News headline image
Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.
From Insulet Corporation
Via Business Wire
News headline image
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
News headline image
Top 4 Health Care Stocks That May Plunge This Quarter ↗
 
Via Benzinga
News headline image
S&P 500 Breaks 6,000 Points, Dow Soars Above 44,000, Small Caps Eye Strongest Week In 4 Years, Tesla Hits $1 Trillion: What's Driving Markets Friday? ↗
The S&P 500 index surged past the 6,000-point milestone, setting fresh record highs, and small-cap stocks are poised for their best weekly performance since April 2024 as investor optimism surrounding... 
Via Benzinga
Topics Stocks
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.